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Knowledge of estrogen receptor (ER) and progester-
one receptor (PR) status has been critical in the evo-
lution of modern targeted therapy of breast cancer
and remains essential for making informed therapeu-
tic decisions. Recently, growth factor receptor HER2/
neu (ERBB2) status has made it possible to provide
another form of targeted therapy linked to the over-
expression of this protein. Presently , pathologists
determine the receptor status in formalin-fixed,
paraffin-embedded sections using subjective, semi-
quantitative immunohistochemistry (IHC) assays and
quantitative fluorescence in situ hybridization for
HER2. We developed a single-tube multiplex TaqMan
(mERPRHER2) assay to quantitate mRNA levels of
ER, PR, HER2, and two housekeeping genes for breast
cancer formalin-fixed, paraffin-embedded sections.
Using data from the discovery sample sets, we evalu-
ated IHC-status-dependent cutoff-point and IHC-sta-
tus-independent clustering methods for the classifica-
tion of receptor status and then validated these results
with independent sample sets. Compared with IHC-
status, the accuracies of the mERPRHER2 assay with
the cutoff-point classification method were 0.98 (95%
CI: 0.971.00), 0.92 (95% CI: 0.880.95), and 0.97
(95% CI: 0.950.99) for ER, PR, and HER2, respec-
tively, for the validation sets. Furthermore, the areas
under the receiver operating-characteristic curves
were 0.997 (95% CI: 0.9941.000), 0.967 (95% CI:
0.9490.985), and 0.968 (95% CI: 0.9151.000) for
ER, PR, and HER2, respectively. This multiplex assay
provides a sensitive and reliable method to quantitate
hormonal and growth factor receptors. (J Mol Diagn
2009, 11:117–130; DOI: 10.2353/jmoldx.2009.080070)
There has been considerable progress in the targeted
therapy of breast cancer in the past few decades. Such
progress has depended to a substantial degree on de-
termining the levels of the estrogen receptor (ER), en-
coded by the ESR1 gene, and progesterone receptor
(PR), encoded by the PGR gene, in breast cancer
cells.1–8 More recently, it has been possible to use over-
expression of human epidermal growth receptor type 2
gene (ERBB2 also known as HER2/neu) to guide yet
another form of targeted therapy according to the spe-
cific features of individual patients with breast can-
cer.9–11 Indeed, tumor overexpression of HER2 has
been used to select women for therapy with trastu-
zumab, a recombinant monoclonal antibody against this
protein. Moreover, high HER2 expression may be asso-
ciated with high risk of recurrence in women receiving an
aromatase inhibitor or tamoxifen as adjuvant therapy.8
It is worth briefly examining tamoxifen and how this
agent has shaped modern breast cancer therapy for
early and advanced disease. Tamoxifen is one of the
oldest and arguably best studied targeted therapies in
medical oncology. ER is essentially the only known ther-
apeutic target for tamoxifen. Thus, in the crucial setting of
adjuvant therapy for early breast cancer, tamoxifen has
been shown to provide clear benefit both in terms of
recurrence-free survival and overall survival.2 More re-
cent trials have also shown very important benefits re-
garding the use of aromatase inhibitors in adjuvant
therapy for postmenopausal women with endocrine-
responsive early breast cancer, particularly with respect
to better disease-free survival compared with tamoxifen
(but not as yet for overall survival).4,5,12 Thus, ER and PR
Celera has provided funding to Guy’s Hospital and St. Thomas Tissue and
Data bank for aquisition of breast cancer specimens. In addition, Lab-
Corp is offering the ER/PR Gene Expression Assay.
Accepted for publication November 5, 2008.
Supplemental material for this article can be found on http://jmd.
amjpathol.org.
Address reprint requests to Sheng-Yung P. Chang, Celera, 1401
Harbor Bay Parkway, Alameda, CA 94502. E-mail: sheng-yung.chang@
celera.com.
Journal of Molecular Diagnostics, Vol. 11, No. 2, March 2009
Copyright © American Society for Investigative Pathology
and the Association for Molecular Pathology
DOI: 10.2353/jmoldx.2009.080070
117
status in malignant tissue from women with operable,
invasive breast cancer provides critically important clas-
sification of outcome and clinical benefit for adjuvant
endocrine or chemoendocrine therapies.
The status of ER-regulated PR has been reported to
improve outcome prediction over ER status alone.13,14 In
Caucasians, approximately 60% to 65% of breast cancer
cases are ER-positive and PR-positive (ER/PR), 15 to
20% are ER/PR-negative (PR), 15% to 20% are ER/
PR, and 5% are ER /PR.15 The response rate to
tamoxifen treatment has been reported to be markedly de-
creased in patients with ER/PR breast tumors.16–18
Starting in the mid 1970s, the levels of ER or PR in fresh
or frozen breast tissue specimens was determined by
quantitative, but technically challenging, radioactive, bio-
chemical ligand-binding assays using dextran-coated
charcoal.19 Almost two decades later, the development
of monoclonal antibodies and the semiquantitative immu-
nohistochemical (IHC) method allowed the measurement
of ER and PR expression in frozen tissue or formalin-
fixed, paraffin-embedded (FFPE) tissue sections.20 Grad-
ually the IHC method became the method of choice as
receptor expression could be related to morphology,21
and it was demonstrated that the prediction of endocrine
therapy response was equivalent to the ligand-binding
assay method.22 The status of hormonal receptors de-
tected by the IHC method can be affected by many
factors, such as fixation, antigen retrieval, antibody type,
and subjective evaluation criteria. A variety of tools have
been developed to improve the performance of IHC test-
ing for ER and PR, including methods for both manual
and image-based scoring of staining results. One exam-
ple is a semiquantitative IHC interpretation system, the
Allred score, developed to grade immunostained slides
based on the percentage and intensity of positively
stained tumor cells.23 However, this approach remains
subjective, semiquantitative, and can be labor intensive.
Many groups reported poor interlaboratory reproducibil-
ity and reliability for testing of hormonal receptors6,24,25
and growth factor receptor HER2 (ERBB2).26,27 Several
reports and editorials have discussed the importance
of accuracy and reproducibility of receptor testing
methods for managing treatment of breast cancer pa-
tients.28–31 The American Society of Clinical Oncology
(ASCO) 2007 Guideline Update Committee acknowl-
edged that there are “deficits in standardization for ER
and PR assays (in particular, IHC), and further efforts at
defining reproducibility and accuracy for particular re-
agents are an important priority.”32 In addition, new
guideline recommendations for growth factor receptor
HER2 (ERBB2) testing were recently published by ASCO
and the College of American Pathologists.33
Since the late 1990s, many groups have developed
molecular assays such as gel-based, semiquantitative
reverse transcription (RT)-PCR assays,34–38 while others
have developed quantitative assays using real-time RT-
PCR and nucleic acid sequence-based amplification
technologies39–42 to measure the mRNA level of ER or
PR in frozen breast biopsy tissue samples, and com-
pared their results to those of the ligand-binding assay or
IHC method. However, only two groups have developed
TaqMan RT-PCR assays to quantitate ER, PR, or HER2
mRNA level individually in archived FFPE speci-
mens.43,44 All groups have reported good concordance
between mRNA level and protein level for ER or PR.
Moreover, several groups developed quantitative PCR
assays for HER2 DNA amplification and RT-PCR for over-
expression of HER2 mRNA in frozen or FFPE breast tumor
specimens.45,46,48–52
In the present study, we report the development and
the performance of a single-tube, one-step, multiplex
TaqMan RT-PCR assay (mERPRHER2) to detect ER,
PR, and HER2 mRNA levels in breast cancer FFPE spec-
imens using two Real-Time PCR instrument platforms. In
addition, we also report the concordance between hor-
monal receptor and growth factor receptor status deter-
mined by the IHC assay and the results of the
mERPRHER2 assay classified with two different meth-
ods using two independent sample sets.
Materials and Methods
Study Subjects
Three sets of FFPE breast tumor sections were used to
develop the RT-PCR assay for ER, PR, and HER2. Two
contemporary sets (sample set 1 and sample set 2) were
provided by Laboratory Corporation of America (LabCorp),
and a third set of archived FFPE breast tumor samples
(sample set 3) was provided by Guy’s and St. Thomas’
Tissue and Data bank (London, United Kingdom). The co-
hort of 291 subjects was diagnosed between 1975 and
2001 with tumor size3 cm, lymph node negative and ER
primary breast tumors, and the use of this cohort was ap-
proved by Guy’s Research Ethics Committee (04/Q0704/
137). The use of these three sample sets for the develop-
ment of classification methods of hormonal and growth
factor receptors, and the number of samples with IHCAllred
scores for each sample set are listed in Table 1.
IHC Assays
Hormonal Receptors
For the IHC assay performed at LabCorp, the FFPE
tissue specimens were mounted on SuperFrost Plus
slides (Fisher Scientific, Hampton, NH) and dried for 30
minutes in a 60°C slide drier. An H&E-stained section was
prepared for each specimen and evaluated for the pres-
ence of tumor cells. The FFPE slides were processed on
Table 1. Description of Sample Sets
Sample Set Subject No. Discovery Validation
Set 1* 67 ER, PR
Set 2 55 HER2 ER, PR†
Set 3 291 ER, PR, HER2‡
*HER2 IHC status was not available. †ER and PR IHC Allred scores
were available for 42 of 55 samples. ‡ER, PR, and HER2 IHC Allred
scores were available for 291, 279, and 272 of 291 samples,
respectively. A total of 400, 388, and 327 samples with ER, PR, and
HER2 IHC status, respectively, were used for data analyses.
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the BenchMark XT Autostainer (Ventana Medical Sys-
tems, Tucson, AZ). The primary monoclonal antibodies
used to detect ER and PR were anti-estrogen receptor
clone 6F11 and anti-progesterone clone 16 (Ventana
Medical Systems), respectively. The sequence of primary
staining events on the automated stainer included: incu-
bations with primary antibodies; application of a biotin-
ylated secondary antibody; binding of avidin-biotin-
horseradish peroxidase complex; and detection with
diaminobenzidine chromagen. After staining, the slides
were counterstained and evaluated by a pathologist for
hormone receptor status, which involved evaluation of at
least 200 tumor cells to determine the percentage of
stained cells, as well as the intensity of staining.
Guy’s and St. Thomas’ Tissue and Data Bank speci-
mens were collected between 1975 and 2001, therefore
the hormonal receptor status was re-evaluated with con-
temporary IHC assays. Each FFPE block was cut in the
following sequence: one section for H&E staining, six
unstained sections on charged slides for IHC, a second
section for H&E staining followed by five 10-m sections
on charged glass slides. All section cutting was per-
formed in RNase-free conditions. On the second H&E-
stained slide, areas with tumor were marked on the cov-
erslip, and this guide slide was sent with the 10-m
sections to facilitate macrodissection of tumor areas for
RNA extraction. To standardize ER or PR status assess-
ment, all cases were re-evaluated. The anti-ER antibody
SP-1 and anti-progesterone receptor PgR636 were used
in a conventional IHC protocol for ER and PR status,
respectively. Briefly, sections were pre-treated by pres-
sure cooking in citrate buffer pH6 before incubating with
SP-1 or PgR636. Sites of antigen-antibody binding were
detected using the Dako REAL Envision system. This set
of specimens was also used for the discovery of a prog-
nostic signature for distant metastasis; therefore ER, PR,
and HER2 status were re-evaluated independently by two
pathologists.53 Any discrepant scores were then as-
sessed jointly and a final score agreed on.
Allred total scores (TS) based on the percentage and
staining intensity of tumor cells were recorded for all three
sets of specimens.23 The distributions of Allred percent-
age of tumor cells, intensity scores, and total scores for
both ER and PR in the three sample sets are listed in
supplemental Tables S1, S2, and S3, at http://jmd.
amjpathol.org.
Growth Factor Receptor HER2
HercepTest reagents (Dako, Carpinteria, CA) with
Dako Autostainer and with Biogenex i6000 autostainer
(San Ramon, CA) were used for sample set 2 and sample
set 3, respectively. Sample set 2 was scored according
to the criteria with cell membrane staining indicated as
3 (strong, complete membrane staining in 10% of
tumor cells), 2 (weak to moderate, complete membrane
staining in 10% of the tumor cells), 1 (faint membrane
staining that involves only a portion of the membrane, in
10% of tumor cells), or 0 (no staining observed, or faint
staining in 10% of the tumor cells). For sample set 3,
HER2 IHC was scored according to the new ASCO-CAP
guidelines.33
RNA Extraction from FFPE Sections
All FFPE section slides used for this study were 4- or
10-m thick with 60% to 80% breast tumor cells. The
FFPE section slides were deparaffinized by soaking them
in xylene for 10 minutes with occasional agitation and
repeated with fresh xylene. The slides were then washed
consecutively with 100% ethanol, 90% ethanol, and 70%
ethanol with 2 minutes for each wash. The slides were
then air dried at room temperature for 5 minutes. Fifteen
microliters of Proteinase K digestion solution 2 mg/ml
Proteinase K (Ambion, Austin, TX), 0.1 mol/L NaCl, 10
mmol/L Tris pH 8.0, 1 mmol/L EDTA, and 0.5% SDS], was
applied to the dried tissue on the slide. The tissue was
then scraped with a sterile surgical blade and transferred
into a 1.5-ml tube containing 185 l Proteinase K diges-
tion solution, and incubated overnight at 55°C for 18 to 24
hours. After incubation, the samples were spun at 14,000
rpm for 5 minutes, and the supernatant was transferred to
a new tube. A mixture of 600 l of 100% ethanol and 400 l
of extraction buffer (5 mol/L guanidium thiocyanate,
31.25 mmol/L Na Citrate, pH 7.0, 0.625% Sarcosyl, and
0.125 mol/L -mercaptoethanol) was added to the super-
natant of each sample, loaded into Zymo-Spin II Columns
(Zymo Research, Orange, CA), spun at 12,000 rpm for
one minute, and repeated until the entire sample had
been spun through the column. The column was washed
once with 200 l of wash buffer (80% ethanol in 10
mmol/L Tris-HCl and 0.1 mmol/L EDTA, pH 8.0), followed
by 13.5 Kunitz units DNase (QIAGEN, Valencia, CA)
treatment at room temperature for 30 minutes. The col-
umns were washed with 200 l wash buffer twice and
then dried by centrifugation for 2 minutes at 12,000 rpm.
The total RNA was then eluted twice with 50 l of Tris-
EDTA buffer that had been heated to 65°C.
The amount of PCR-amplifiable RNA was quantitated
by one-step RT-PCR using primers for the housekeeping
(HSK) gene, NUP214, and compared with a serially
diluted control, Universal Human Reference RNA
(Stratagene, La Jolla, CA). The recovery of amplifiable
RNA depends on the age of the FFPE specimen and RNA
extraction methods. The recovery of amplifiable RNA
from one 4-m breast cancer FFPE section ranges from
0.5 ng to 25 ng.
A New Approach for Determining Normalization
Factor
The top two most stable HSK genes, PPIG and NUP214,
were previously determined by the profiling of 138 breast
cancer FFPE samples,53 and they were used to validate
the novel approach of determining the normalization fac-
tor for RNA amount in each RT-PCR reaction. Fifty-eight
human total RNA samples (see supplemental Table S4 at
http://jmd.amjpathol.org) from various tissue types were
used to demonstrate the feasibility of using two TaqMan
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probes labeled with identical fluorescent reporter dye (see
supplemental Table S5 at http://jmd.amjpathol.org) to deter-
mine the normalization factor of total RNA input amount in
each sample. The concentration of each RNA sample was
determined using RiboGreen quantitation assay (Invitrogen,
Carlsbad, CA), and 20 ng of total RNA was used for each
reaction. The expression levels of two HSK genes, NUP214
or PPIG, were quantitated in independent simplex reactions
using either NUP214 probe or PPIG probe labeled with the
same fluorescent reporter dye using the 7900 Real-Time
PCR System (7900 system; Applied Biosystems, Foster
City, CA). The average of NUP214 and PPIG expression
levels was then compared with the composite NUP214 and
PPIG expression level quantitated using both NUP214 and
PPIG TaqMan probes in a single reaction.
Single-Tube, One-Step, Multiplex TaqMan
Assays
mERPRHER2 RT-PCR Assay on the 7500 System
Table 2 lists gene IDs, gene symbols, the oligonucle-
otide sequences of PCR primers, the accession numbers
of RefSeq and GenBank in National Center for Biotech-
nology Information of known splice variants amplified by
the designed PCR primers for ESR1, PGR, ERBB2
(HER2), and the two HSK genes, NUP214 and PPIG, and
the oligonucleotide sequences and fluorescent reporters
of all TaqMan probes for the 7500 Real-Time PCR System
(7500 system; Applied Biosystems, Foster City, CA).
Quantitative detection of mRNA levels of ESR1, PGR,
ERBB2 (HER2), and two HSK genes in a single tube was
accomplished through one-step, five-plex TaqMan RT-PCR
assay. Each reaction contained 50 mmol/L of Tricine, 115
mmol/L KOAc (pH 8.0), 4.5 mmol/L Mn(OAc)2, 7.4% glyc-
erol, 400 mol/L dATP, 400 mol/L dGTP, 400 mol/L
dCTP, 800 mol/L dUTP, 1% dimethyl sulfoxide, 50 nmol/L
NPR (provided by Applied Biosystems) in 5% Tween-20,
0.12mol/L enhancer (Abbott, Abbott Park, IL), 0.08 unit/L
uracil N-glycosylase, 0.4 unit/L Z05 DNA polymerase (Ab-
bott), 500 nmol/L of each primer (Applied Biosystems), 250
nmol/L of each TaqMan probe (Applied Biosystems), and
approximately 0.2 to 1 ng of amplifiable RNA extracted from
the FFPE specimen. TRE and PHO labeled TaqMan probes
were provided by Applied Biosystems, (United States Pat-
ents 6080852, 5847162, 6025505, and 6017712). The ther-
mocycling parameters were as follows: 50°C for 2 minutes;
95°C for 1 minute; 60°C for 30 minutes; 95°C for 15 seconds
and 58°C for 35 seconds for 42 cycles for the 7500 system.
In addition to each RNA sample from the FFPE specimen,
25 ng of the Universal Human Reference RNA was included
as the control in each amplification plate, and all sam-
ples were run in duplicate reactions.
mERPR RT-PCR Assay on the 7900 System
A single-tube multiplex TaqMan assay for ER, PR, and
two HSKs (mERPR assay) was developed for the 7900
system. The mERPRHER2 assay for the 7900 system
was not developed due to the unavailability of a compat-
ible florescent dye for HER2 for the optical system on the
7900 system. The supplemental Table S5 at http://jmd.
amjpathol.org lists the oligonucleotide sequences, orien-
tations, fluorescent reporters, and quenchers of all TaqMan
probes for the 7900 system.
Quantitative detection of mRNA levels of ER, PR, and
two HSK genes in a single tube was also accomplished
through one-step multiplex TaqMan RT-PCR with a 384-
well plate using the 7900 system. Each 15-l reaction
contained 50 mmol/L of Tricine, 115 mmol/L KOAc (pH
8.0), 4.5 mmol/L Mn(OAc)2, 9.6% glycerol, 400 mol/L
dATP, 400 mol/L dGTP, 400 mol/L dCTP, 800 mol/L
dUTP, 1% dimethyl sulfoxide, 0.3 mol/L 6-ROX (Invitro-
gen, Carlsbad, CA) in 5% Tween-20, 0.12 mol/L en-
hancer (Abbott), 0.08 unit/L uracil N-glycosylase, 0.4
unit/L Z05 DNA polymerase (Abbott), 500 nmol/L of
each primer, 200 nmol/L TET-labeled (or NED-labeled)
TaqMan probes for each HSK gene, 250 nmol/L FAM-
labeled TaqMan probe for ER, 250 nmol/L VIC-labeled
TaqMan probe for PR, and approximately 0.5 to 1 ng of
amplifiable RNA extracted from FFPE specimen. The
thermocycling parameters for the 7900 system are as
follows: 50°C for 2 minutes; 95°C for 1 minute; 60°C for 30
minutes; 95°C for 15 seconds and 58°C for 30 seconds
for 42 cycles. In addition to each RNA sample from FFPE
specimens, 25 ng of the Universal Human Reference RNA
(Stratagene) was included as the control in each amplifica-
tion plate. All samples on the plate were run in duplicate.
The results from the 7900 system are described in Supple-
mental Tables S6 to S10 and Figures S1A, S1B, S2A, and
S2B at http://jmd.amjpathol.org.
Table 2. Genes and Information of RT-PCR Primers and TaqMan Probes in the mERPRHER2 Assay for the 7500 System
Gene
ID
Gene
symbol Forward primer sequence Reverse primer sequence Reporter Probe sequence
2099 ESR1* 5-TCTGCAGGGAGAGGAGTTT-3 5-GGTCCTTCTCTTCCAGAGACTT-3 FAM 5-TGTGCCTCAAATCTA-3
5241 PGR* 5-TCGAGTCATTACCTCAGAAGAT-3 5-CCCACAGGTAAGGACACCATA-3 TRE§ 5-TGACAGCCTGATGCTTCAT-3
2064 ERBB2† 5-CAGCCCTGGTCACCTACAA-3 5-GGGACAGGCAGTCACACA-3 PHO§ 5-TGAGTCCATGCCCAATCC-3
8021 NUP214‡ 5-CATTTGCTTTATAAAAGACCACTG-3 5-CCACTCCAAGTCTAGAACATCA-3 VIC 5-TCAGGAAATTCGGCGCCTT-3
9360 PPIG‡ 5-GCCAACAGAGGGAAGGATA-3 5-GAGGAGTTGGTTTCGTTGTTA-3 VIC 5-ATGGTTCACAGTTCTTC-3
*ESR1 and PGR have at least four alternative splice variants. NM_000125, AF258449, AF258450, and AF258451 are the accession numbers of the
variants for ESR1. NM_000926, AB085683, AB085844, and AB085845, are the accession numbers of the variants for PGR. †NM_004448 and
NM_001005862 are the annotated accession numbers of the variants for ERBB2. ‡NM_005085 and NM_004792 are the accession numbers of the
variants for NUP214 and PPIG, respectively. For each of these genes, RT-PCR primers were designed to amplify a region shared by all listed splice
variants. The amplicon sizes are 104-bp, 80-bp, 95-bp, 123-bp, and 61-bp, for ESR1, PGR, ERBB2, NUP214, and PPIG, respectively. §TRE and PHO
labeled probes were provided by Applied Biosystems. All five TaqMan probes have minor-groove binder and non-fluorescent quencher at 3 termini.
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FFPE Section-to-Section Reproducibility
To determine FFPE section-to-section reproducibility, five
sequential sections from each of 10 breast cancer tumor
FFPE samples (BioChain Institute, Hayward, CA) were ob-
tained. Before RNA was isolated, the slide was checked to
ensure that all sections from each sample were identical in
size and shape. Total RNA was extracted from these 50
sections and the recovery was determined using NanoDrop
(Thermo Scientific, Wilmington, DE). The amplifiable RNA
was determined by a TaqMan RT-PCR assay for the HSK
gene, NUP214. ER, PR, and HER2 mRNA levels in each
section were determined using the mERPRHER2 assay.
Data Analysis
The ER, PR, and HER2 mRNA expression levels in each
FFPE clinical sample were calculated using the 		CT
method.54 First, the average CT (cycle threshold) of du-
plicate reactions of each gene of interest was calculated
for each sample and the control sample, Universal Hu-
man Reference RNA. Then the ER, PR, and HER2 mRNA
expression levels were normalized with the HSK gene
expression level for each FFPE and the control sample.
Finally the HSK-normalized ER, PR, and HER2 expression
levels in each FFPE sample were further compared with
the HSK-normalized ER, PR, and HER2 expression levels
in the control sample, respectively. Therefore, the relative
expression level of each gene of interest in each FFPE
sample, is presented as 		CT 
 (1)  	CT sample (CT
of gene of interest  CT of HSK genes)  	CT control (CT
of gene of interest  CT of HSK genes)]. A minus one
factor is included to graphically illustrate higher expression
above lower expression. When CT value was not reported,
then a CT of 42 was used for the calculation of 		CT.
Statistical Analysis
For ER and PR classification, the results of the
mERPRHER2 assay from sample set 1 and combined
sample sets 2 and 3 were used as the discovery and
validation sets, respectively. For HER2 classification, the
results of the mERPRHER2 assay from sample sets 2
and 3 were used as the discovery and validation sets,
respectively.
Area under the receiver operating characteristic curve
(AUC) measures the ability of the assay to discriminate
between positive and negative status of ER, PR, or normal-
and over-expression status of HER2 across the entire range
of 		CT values. AUC was computed based on the receiver
operating characteristic function available from the Mayo
Clinic (http://mayoresearch. mayo.edu/mayo/research/biostat/
splusfunctions.cfm) and confidence intervals (CI) for the AUC
were calculated using the variance estimate described by
Delong et al.55
We used two different methods to classify the status of
ER, PR, and HER2. An IHC-status-dependent 		CT cut-
off-point method was used to determine the hormonal
and growth factor receptor status. Using IHC status as
the gold standard, an Allred score 3 defines positive
hormonal status (ER or PR),23 and an intensity score
of HER2 3 defines HER2 overexpression.33 The 		CT
cutoff point for classification of each marker was empiri-
cally selected based on the diagnostic metrics of sensi-
tivity, specificity, positive predictive value, negative pre-
dictive value, and accuracy from the comparisons with
IHC status using various 		CT cutoff points. A 		CT cutoff
point for classification of each marker was selected using
the data from their respective discovery sets. The selected
		CT cutoff points were then applied to classify ER, PR and
HER2 status of samples in their respective validation sets.
An IHC-status-independent classification method was
established by developing Gaussian mixture models as
implemented in MCLUST software for the R programming
language (http://www.R-project.org)56 based solely on
ER 		CT, PR 		CT, and HER2 		CT measurements of
subjects in their respective discovery sets.57–61 The
Bayesian Information Criterion was used to determine the
best fitting model. For ER and HER2 measures, the best
model was a mixture of two Gaussian distributions with
equal variance. For PR, since the best model by Bayesian
Information Criterion was a single Gaussian distribution,
which would not be helpful for classification purposes, a
mixture model of two Gaussian distributions with equal
variance was used. The mixture models estimated from
the discovery data were then used to classify an inde-
pendent set of validation subjects to the cluster for which
they had the highest probability of membership based on
their 		CT measurements.
The diagnostic metrics of sensitivity, specificity, posi-
tive predictive value, negative predictive value, and ac-
curacy were calculated for both discovery and validation
sets. The agreement coefficient, Cohen’s kappa,62 was
used to evaluate the agreement between the IHC status
and the status determined using the results from the
mERPRHER2 assay for the 		CT cutoff-point and clus-
tering methods. In addition, the square of Pearson’s cor-
relation coefficient was used to assess the degree of
correlation between two instrument platforms.
Results
A New Approach for Determination of
Normalization Factor
To obtain more accurate normalization of RNA input
amount and to accommodate three genes of interest,
ESR1, PGR, and ERBB2, in a multiplex TaqMan assay
with four different fluorescent reporters, we designed a
novel approach of determining the expression levels of
two HSK genes using two TaqMan probes labeled with
the same fluorescent reporter.
Two HSK genes, NUP214 and PPIG, expressed at
relatively constant levels in breast tumor FFPE specimens
were selected to validate our approach. mRNA levels of
NUP214 and PPIG were averaged from independent re-
actions with NUP214 or PPIG probes, and compared with
the NUP214 and PPIG composite mRNA level in a single
co-amplification reaction. The comparison of 58 total RNA
samples from various tissues using two amplification for-
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mats is shown in Figure 1. The two different formats of
determining HSK gene expression levels correlated well
with a correlation coefficient, r2, of 0.9742 (P  0.0001).
FFPE Section-to-Section Reproducibility
Total RNA and amplifiable RNA from each of five sequen-
tial sections of 10 breast cancer tumor FFPE samples
were determined by absorbance at 260 nm and the Taq-
Man RT-PCR assay for the housekeeping gene NUP214.
The recoveries of amplifiable RNA from each of 5 sec-
tions of 10 FFPE samples are shown in Figure 2. The
average percentage of the amplifiable RNA relative to the
total RNA measured by absorbance at 260 nmol/L of
each sample is shown above each bar. The average
amplifiable RNA from 10 FFPE samples varied from 70 ng
(S4) to 1300 ng (S1). Figure 3 illustrates the distributions
of ER, PR, and HER2 		CT values from 5 sections of 10
FFPE samples, respectively. The relatively larger variations
of the PR 		CT values in samples S2, S4, and S8 were due
to later CT resulting from lower PR expression levels. There
was no correlation between the variation of amplifiable RNA
recovery and ER, PR, or HER2 		CT values.
Classification of Hormonal Receptor Status
Three breast cancer tumor FFPE sample sets with avail-
able ER and PR IHC Allred total scores listed in Table 1
were used to determine the classifications of ER and PR
status. Sample set 1 with 67 samples, and combined
sample sets 2 and 3 with 333 samples were used as the
discovery and validation sets, respectively. Both ER
mRNA and PR mRNA were detected in all clinical spec-
imens using the mERPRHER2 assay.
Estrogen Receptor
The ER 		CTvalues of 67 RNA samples of the discovery
set using the mERPRHER2 assay were calculated, and
the distribution of ER 		CT values in the discovery set was
bimodal, as reported previously.44 The AUC of ER 		CT
values from the discovery set was 0.989 (95% CI: 0.972–
1.000). The performance measurements of sensitivity,
specificity, positive predictive value, negative predictive
value, and accuracy for the ER classification based on the
IHC ER status were compared using various 		CT cutoff
points (Figure 4A). A 		CT cutoff point of 1.5 with 94%
accuracy was empirically selected to divide 67 ER 		CT
values into two groups in Figure 4B. The distribution of 67
IHC ER Allred total scores and the classifications of ER
status by both the IHC-status-dependent 		CT cutoff-point
and the IHC-status-independent clustering methods are
listed in Table 3. Two Allred TS0 samples and two Allred
TS3 samples were classified as ER and ER, respec-
tively, by the 		CT cutoff-point method. All Allred TS0 sam-
ples were classified as ER correctly, and two Allred TS3
samples were classified as ER by the clustering method.
When compared with IHC ER status, the kappa coefficient
of the clustering method, 0.924 (95% CI: 0.821–1.000) was
higher than that of the 		CT cutoff-point method, 0.842
(95% CI: 0.6930.992) (Table 4).
Both the 		CT cutoff point of 1.5 and the model param-
eters for the clustering method derived from the discovery
set were applied to classify the ER status of samples in the
validation set. The validation set consisted of two indepen-
dent subsets, sample set 2 and sample set 3 listed in Table
1. Forty-two samples with ER IHC Allred scores in sample
set 2 and 291 samples with ER IHC Allred scores in sample
set 3 were used to validate ER classification. The 291 ar-
chived specimens in sample set 3 were originally identified
as ER between 1975 and 2001. The ER and PR status was
re-evaluated in these specimens with contemporary IHC
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Figure 1. Correlation of housekeeping gene normalization determined using
two different amplification formats. The correlation coefficient, r2, between
the expression levels of housekeeping genes using two different formats was
0.9742.
Figure 2. RNA recovery of sequential FFPE sections. The distributions of
recovered amplified RNA of 5 sequential sections from 10 FFPE breast tumor
specimens. The average percentage of amplifiable RNA relative to the total
RNA measured by absorbance of each sample is shown above each bar.
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assays, and 8 of 291 samples (3%) were re-classified as
IHC ER. The AUC of ER 		CT values from the validation
set was 0.997 (95% CI: 0.994–1.000). The distribution of
IHC Allred total scores of the entire 333 samples and the
classifications of ER status by both the IHC-status-depen-
dent 		CT cutoff-point and the IHC-status-independent
clustering methods of the validation set are listed in Table 3.
One Allred TS0 sample and four Allred TS3 samples were
classified as ER and ER, respectively, by the 		CT
cutoff-point method. All IHC ER samples were cor-
rectly classified as ER by the clustering method.
However, an additional six Allred TS4 to TS6, and one
Allred TS8 samples were classified as ER by the
clustering method. When compared with IHC ER sta-
tus, the kappa coefficient of the clustering method
was 0.759 (95% CI: 0.6230.895), lower than 0.870
(95% CI: 0.7580.982) of the 		CT cutoff-point
method (Table 4).
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Figure 3. Reproducibility of the status of hormonal and growth factor receptors in sequential FFPE sections. A, B, and C: The 		CT distributions of ER, PR, and
HER2, respectively, of 5 sequential sections from 10 FFPE breast tumor specimens.
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Figure 4. ER classification. A: Performance
measurements of classifications based on ER
IHC status using various 		CT cutoff points of
the discovery sample set. B: Classification of the
discovery sample set using the 		CT cutoff
point of 1.5. C: Distribution of ER 		CT values
with IHC status of the discovery and validation
sample sets. PPV: positive predictive value;
NPV: negative predictive value.
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Progesterone Receptor
The performance measurements of the PR classifica-
tion of 67 		CT values based on the IHC PR status were
compared using various 		CT cutoff points (Figure 5A).
The AUC of PR 		CT values from the discovery set was
0.987 (95% CI: 0.969–1.000). A 		CTcutoff point of 0.5
with 94% accuracy was empirically selected to divide 67
PR 		CT values into two groups in Figure 5B. The distri-
bution of 67 IHC PR Allred total scores and the classifi-
cations of PR status by both the IHC-status-dependent
		CT cutoff-point and the IHC-status-independent clus-
tering methods are listed in Table 5. One Allred TS0
sample was classified as PR by both the 		CT cutoff-
point and clustering methods. One Allred TS3 and two
Allred TS5 samples were classified as PR by the 		CT
cutoff-point method, and three additional samples (one
Allred TS4, one Allred TS5, and one Allred TS6) were also
classified as PR by the clustering method. When com-
pared with IHC PR status, the kappa coefficients of the
		CT cutoff-point and clustering methods were 0.861
(95% CI: 0.7300.993) and 0.767 (95% CI: 0.607
0.928), respectively (Table 6).
Both the 		CT cutoff point of 0.5 and the model pa-
rameters for the clustering method derived from the dis-
covery set were applied to classify PR status of samples
in the validation set. The validation set also consisted of
two independent subsets, sample set 2 and sample set 3
listed in Table 1. Forty-two samples with PR IHC Allred
scores and 279 samples with PR IHC Allred scores from
sample set 2 and set 3, respectively, were used to vali-
date PR classification. The AUC of PR 		CT values from
the validation set was 0.967 (95% CI: 0.9490.985). The
distribution of IHC Allred total scores and the classifica-
tions of PR status of 321 validation samples by both the
		CT cutoff-point and the IHC-status-independent clus-
tering methods are listed in Table 5. Twelve (11 Allred
TS0 and one Allred TS2) and eight samples (seven Allred
TS0 and one Allred TS2) were classified as PR by the
		CT cutoff-point method and the clustering method,
respectively. Fourteen Allred TS3 and TS4 samples were
classified as PR by the 		CT cutoff-point method, and
additional six samples (four Allred TS3, one Allred TS5
and one Allred TS6) were classified as PR by the clus-
tering method. When compared with IHC PR status, the
kappa coefficients of the 		CT cutoff-point and cluster-
ing methods were similar but lower than those of the
discovery set, 0.664 (95% CI: 0.5440.784) and 0.669
(95% CI: 0.5560.782), respectively (Table 6).
Classification of Overexpression of Growth
Factor Receptor HER2
The HER2 		CT values of 55 samples of the HER2 dis-
covery set (sample set 2 in Table 1) using the
mERPRHER2 assay were determined. The AUC of
HER2 		CT values from the discovery set was 0.968
(95% CI: 0.924–1.000). The HER2 		CT values were
compared with HER2 IHC scores with HER2 IHC 3
(HER2-over) defined as samples expressing above the
normal level of HER2 (HER2-norm). The performance
measurements of HER2 classification based on the HER2
IHC status were compared using various HER2 		CT
Table 3. Classification of ER Status of the Discovery and Validation Sets Using the 		CT Cutoff-Point and Clustering Methods
Allred TS*
Discovery (n 
 67) Validation (n 
 333)
IHC (% of total)
		CT cutoff-
point Clustering
IHC (% of total)
		CT cutoff-
point Clustering
ER ER ER ER ER ER ER ER
0 17 2 15 0 17 17 1 16 0 17
2 0 0 0 0 0 2 0 2 0 2
ER† 17 (25%) 2 15 0 17 19 (6%) 1 18 0 19
3 2 0 2 0 2 4 0 4 0 4
4 0 0 0 0 0 2 2 0 1 1
5 3 3 0 3 0 6 6 0 4 2
6 2 2 0 2 0 31 31 0 28 3
7 12 12 0 12 0 110 110 0 110 0
8 31 31 0 31 0 161 161 0 160 1
ER‡ 50 (75%) 48 2 48 2 314 (94%) 310 4 303 11
*Allred total score. †Total number of specimens with Allred TS0 and TS2 in each set. ‡Total number of specimens with Allred TS3 to TS8 in
each set.
Table 4. Summary of the Performance of ER Classification
Discovery (n 
 67) Validation (n 
 333)
		CT cutoff-point Clustering 		CT cutoff-point Clustering
Sensitivity 0.96 (0.861.00) 0.96 (0.861.00) 0.99 (0.971.00) 0.96 (0.940.98)
Specificity 0.88 (0.640.99) 1.00 (0.801.00) 0.95 (0.741.00) 1.00 (0.821.00)
PPV 0.96 (0.861.00) 1.00 (0.931.00) 1.00 (0.981.00) 1.00 (0.991.00)
NPV 0.88 (0.640.99) 0.89 (0.670.99) 0.82 (0.600.95) 0.63 (0.440.80)
Accuracy 0.94 (0.850.98) 0.97 (0.901.00) 0.98 (0.971.00) 0.97 (0.940.98)
Kappa 0.842 (0.6930.992) 0.924 (0.8211.000) 0.870 (0.7580.982) 0.759 (0.6230.895)
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cutoff points (Figure 6A). A 		CT cutoff point of 3.5 with
91% accuracy was empirically selected to divide 55
HER2 		CT values into two groups in Figure 6B. The
distribution of HER2 IHC scores and the classification of
HER2 status by both 		CT cutoff-point and clustering
methods of the discovery set are listed in Table 7. Using
a 		CT cutoff point of 3.5 for the classification of HER2
expression status, one HER2 IHC 2 sample were clas-
sified as HER2-over, and four samples with HER2 IHC 3
were classified as HER2-norm. Using the clustering
method, all 38 samples with HER2 IHC 0 to 2 were
classified correctly. Nine of 17 samples with HER2 IHC
3 were classified as HER2-norm. When compared with
IHC HER2 expression status, the kappa coefficients of
the 		CT cutoff-point and clustering methods for classi-
fication of HER2 expression status of the discovery set
were 0.776 (95% CI: 0.5920.961) and 0.551 (95% CI:
0.3120.791), respectively (Table 8).
Both the 		CT cutoff point of 3.5 and the model
parameters for the clustering method derived from the
discovery set were applied to classify HER2 expres-
sion status of 272 samples in the validation set. The
AUC of HER2 		CT values from the validation set was
0.968 (95% CI: 0.915–1.000). The distribution of 272
HER2 IHC scores and the classification of HER2 status
by both 		CT cutoff-point and clustering methods of
the validation set are listed in Table 7. Using the 		CT
cutoff point of 3.5, four samples (two HER2 IHC 0 and
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Figure 5. PR classification. A: Performance
measurements of classifications based on PR
IHC status using various 		CT cutoff points of
the discovery sample set. B: Classification of the
discovery sample set using the 		CT cutoff
point of 0.5. C: Distribution of PR 		CTvalues
with IHC status of the discovery and validation
sample sets.
Table 5. Classification of PR Status of the Discovery and Validation Sets Using the 		CT Cutoff-Point and Clustering Methods
Allred TS*
Discovery (n 
 67) Validation (n 
 321)
IHC (% of total)
		CT cutoff-
point Clustering
IHC (% of total)
		CT cutoff-
point Clustering
PR PR PR PR PR PR PR PR
0 20 1 19 1 19 35 11 24 7 28
2 0 0 0 0 0 9 1 8 1 8
PR† 20 (30%) 1 19 1 19 44 (14%) 12 32 8 36
3 1 0 1 0 1 36 24 12 20 16
4 3 3 0 2 1 28 26 2 26 2
5 11 9 2 8 3 51 51 0 50 1
6 11 11 0 10 1 47 47 0 46 1
7 7 7 0 7 0 58 59 0 58 0
8 14 14 0 14 0 57 56 0 57 0
PR‡ 47 (70%) 44 3 41 6 277 (86%) 263 14 257 20
*Allred total score. †Total number of specimens with Allred TS0 and TS2 in each set. ‡Total number of specimens with Allred TS3 to TS8 in
each set.
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two HER2 1) were classified as HER2-over, and three
HER2 IHC 3 samples was classified as HER2-norm.
Using the clustering method, all 255 HER2-norm sam-
ples were classified correctly, but 12 of 17 HER2 IHC
3 samples were classified as HER2-norm. When
compared with IHC HER2 expression status, the kappa
coefficients of the 		CT cutoff-point and clustering
methods for classification of HER2 overexpression
of the validation set were 0.786 (95% CI: 0.633
0.940) and 0.439 (95% CI: 0.1820.696), respectively
(Table 8).
Diagnostic Metrics of mERPRHER2 Assay
The performance measurements of the mERPRHER2
assay, sensitivity, specificity, positive predictive value,
negative predictive value, accuracy, and kappa coeffi-
cient, for ER, PR, and HER2 overexpression with the
discovery and validation sets are listed in Tables 4, 6,
and 8, respectively.
All 		CT values from the discovery and validation sets
were sorted, and then plotted using 		CT of 1.5, 0.5, and
3.5 as the cutoff points for ER, PR, and HER2, respec-
tively, and compared with IHC ER, PR, and HER2 status
in Figures 4C, 5C, and 6C, respectively.
Discussion
Several factors, such as the size of the tissue biopsy, the
type of the fixative, the age of the paraffin block, or the
degree of chemical modification, affect the recovery of
amplifiable RNA from FFPE sections. Insufficient amounts
of recovered RNA from FFPE sections for profiling of a
panel of genes for breast cancer studies have been
reported.63,64 Therefore, we set out to develop a multi-
plex TaqMan assay to quantitate mRNA levels of ESR1,
PGR, ERBB2 (HER2), and two HSK genes in a single tube
for breast cancer diagnosis. We evaluated the perfor-
mance of the mERPRHER2 assay with three sets of
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Figure 6. HER2 classification. A: Performance
measurements of classification based on HER2
IHC status using various 		CT cutoff points of
the discovery sample set. B: Classification of the
discovery sample set using the 		CT cutoff
point of 3.5. C: Distribution of HER2 		CTval-
ues with IHC status of the discovery and valida-
tion sample sets.
Table 6. Summary of the Performance of PR Classification
Discovery (n 
 67) Validation (n 
 321)
		CT cutoff-point Clustering 		CT cutoff-point Clustering
Sensitivity 0.94 (0.820.99) 0.87 (0.740.95) 0.95 (0.920.97) 0.93 (0.890.96)
Specificity 0.95 (0.751.00) 0.95 (0.751.00) 0.73 (0.570.85) 0.82 (0.670.92)
PPV 0.98 (0.881.00) 0.98 (0.871.00) 0.96 (0.930.98) 0.97 (0.940.99)
NPV 0.86 (0.650.97) 0.76 (0.550.91) 0.70 (0.540.82) 0.64 (0.500.77)
Accuracy 0.94 (0.850.98) 0.90 (0.800.96) 0.92 (0.880.95) 0.91 (0.880.94)
Kappa 0.861 (0.7300.993) 0.767 (0.6070.928) 0.664 (0.5440.784) 0.669 (0.5560.782)
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breast cancer specimens using two classification meth-
ods on two instrument platforms.
A recent review discussed the current issues in ER and
HER2 testing for breast cancer by IHC.31 In addition, the
intratumoral heterogeneity and the various degree of
HER2 DNA amplification in breast tumor specimens us-
ing IHC and fluorescence in situ hybridization assays
have been reported.65,66 Therefore, it is important to
demonstrate the reproducibility of sequential FFPE sec-
tions using the mERPRHER2 assay. Our results in Fig-
ure 3 demonstrated good reproducibility for samples with
ER, PR, or HER2-over status, and better than that of
the group of ER, PR, or HER2-norm, respectively,
because of the later CT values resulting from the relatively
low abundance of mRNA levels.
The lack of intermediate Allred scores in the ER dis-
covery sample set (only two Allred TS3 and no Allred TS2
or TS4 samples) rendered the 		CT cutoff-point selection
more challenging; therefore the more conservative lower
		CT cutoff point of 1.5 was selected. Approximately two
thirds of breast cancer has ER status, however sample
set 3 of the validation sample set in our study was mostly
ER (97%). Consequently, the percentage of samples
with HER2 overexpression (HER2 IHC 3) in this set was
also lower than the generally observed 25% to 30% with
HER2 overexpression.17 The kappa coefficients of ER
classification using the 		CT cutoff-point method for the
discovery and validation sets were similar, 0.842 and
0.870, respectively (Table 4). In contrast, the kappa co-
efficient of ER classification using the clustering method
dropped from 0.924 to 0.759 for the validation set (Table
4). The discordant results between the IHC ER assay and
the mERPRHER2 assay were 9 (2%) and 13 (3%) of a
total of 400 samples using the 		CT cutoff-point method
(Figure 4C) and the clustering method, respectively.
The ER mRNA expression in breast tumor specimens is
bimodal as represented by the sigmoidal transition between
RT-PCR–and RT-PCR groups (see Figure 4C). Both IHC
ER/PCR ER and IHC ER/PCR ER groups were iden-
tified by IHC methods with different antibodies used by the
two clinical sites. Therefore, it is likely that the performance
of the different antibodies was similar even though the SP1
clone used by Guy’s Hospital has been indicated to have
higher affinity and a more robust performance.31,67 The
group of IHC ER but PCR ER subjects, currently not
being identified, may merit consideration of endocrine ther-
apy, but clinical data do not exist on the benefit of endocrine
therapy in this situation.
The total number of IHC ER samples, 36 of 400 (9%) in
the discovery and validation sets was relatively small, there-
fore the cutoff point of 1.5 requires additional validation with
a larger number of samples even though the kappa coeffi-
cients of the agreement of ER status between the IHC assay
and the mERPRHER2 assay with the 		CT cutoff-point
method was “almost perfect”68 based on the interpretation
of Cohen’s kappa for both discovery and validation sets.
The agreement of ER status between the IHC assay and the
mERPRHER2 assay with the 		CT cutoff-point method
was slightly higher than those reported by Cronin et al43
(kappa
 0.825; n
 62) and Ma et al44 (kappa
 0.83; n

852). Subsequently, two additional groups reported the
agreement of ER status between the IHC assay and the ER
TaqMan assay in the Oncotype DX as kappa 
 0.81 (n 

149)63 and kappa 
 1.0 (n 
 80).64
In contrast to ER mRNA expression, PR mRNA expres-
sion is more continuous as represented by the gradual
Table 7. Classification of HER2 Overexpression of the Discovery and Validation Sets Using the 		CT Cutoff-Point and Clustering
Methods
HER2 IHC
score
Discovery (n 
 55) Validation (n 
 272)
IHC
(% of total)
		CT cutoff-
point Clustering
IHC
(% of total)
		CT cutoff-
point Clustering
HER2-
over
HER2-
norm
HER2-
over
HER2-
norm
HER2-
over
HER2-
norm
HER2-
over
HER2-
norm
0 10 0 10 0 10 200 2 198 0 200
1 20 0 20 0 20 53 2 51 0 53
2 8 1 7 0 8 2 0 2 0 2
HER2-norm* 38 (69%) 1 37 0 38 255 (94%) 4 251 0 255
3 17 13 4 8 9 17 14 3 5 12
HER2-over† 17 (31%) 13 4 8 9 17 (6%) 14 3 5 12
*Total number of specimens with HER2 IHC scores 0, 1, and 2. †The number of specimens with HER2 IHC score 3.
Table 8. Summary of the Performance of HER2 Classification
Discovery (n 
 55) Validation (n 
 272)
		CT cutoff-point Clustering 		CT cutoff-point Clustering
Sensitivity 0.76 (0.500.93) 0.53 (0.280.77) 0.82 (0.570.96) 0.71 (0.440.90)
Specificity 0.97 (0.861.00) 1.00 (0.911.00) 0.98 (0.960.99) 1.00 (0.991.00)
PPV 0.93 (0.661.00) 1.00 (0.631.00) 0.78 (0.520.94) 1.00 (0.481.00)
NPV 0.90 (0.770.97) 0.81 (0.670.91) 0.99 (0.971.00) 0.96 (0.920.98)
Accuracy 0.91 (0.800.97) 0.84 (0.710.92) 0.97 (0.950.99) 0.96 (0.920.98)
Kappa 0.776 (0.5920.961) 0.551 (0.3120.791) 0.786 (0.6330.940) 0.439 (0.1820.696)
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increase of 		CT values from the RT-PCR group to the
RT-PCR group in Figure 5C. The kappa coefficients of PR
status between the IHC assay and the mERPRHER2 as-
say dropped from the discovery to validation set using both
		CT cutoff-point and the clustering methods (Table 6).
When compared with ER discordant results, the percentage
of samples with discordant results between PR IHC assay
and the mERPRHER2 assay were larger, 30 (8%) and 25
(6%) of a total of 388 samples using 		CT cutoff-point
method (Figure 5C) and the clustering method, respec-
tively, which is likely due to the more continuous values for
expression of PR. Therefore, we will continue to evaluate the
performance of both classification methods for PR status.
The agreement of PR status between the IHC assay and the
mERPRHER2 assay with the 		CT cutoff-point method for
the validation set, was similar to those reported by Cronin et
al43 (kappa
 0.674; n
 62) and Ma et al44 (kappa
 0.70;
n 
 852). However, subsequently two groups reported
lower agreement for PR status, kappa of 0.48 (n 
 149)63
and kappa of 0.57 (n
 80), using the PR TaqMan assay in
the Oncotype DX.64
The regulation of PR expression is complex and not
fully understood at present. Two estrogen-regulated pro-
moters and several alternative splice variants have been
reported.16,69,70 The differences in the agreement be-
tween various IHC and RT-PCR assays might be the
result of the PR antibodies interrogating different
epitopes for the IHC assays and/or different mRNA vari-
ants for RT-PCR assays. In addition, the RT-PCR assay
doesn’t discern PR-A from PR-B isoforms, which are
translated from different translation initiation sites. Sev-
eral studies reported interesting findings of cross talk
between the estrogen and growth factor HER2 signaling
pathways, which resulted in decreased PR levels, and
the tumors eventually becoming tamoxifen resistant.71–74
The performances of ER and PR classifications using
IHC-status-dependent 		CT cutoff-point and IHC-status-
independent clustering methods were similar (Tables 4
and 6). However, it is interesting that the performance of
classification of HER2 overexpression between the IHC-
status-dependent 		CT cutoff-point and IHC-status-
independent clustering methods were quite different (Ta-
ble 8). Using the clustering method, 9 of 17 (53%) and 12
of 17 (70%) samples with HER2 IHC 3 samples were
classified as HER2-norm for the discovery and validation
sets, respectively. Based on the clustering results, a
HER2 		CT cutoff point of 5.0 instead of 3.5 could have
been selected to classify HER2 status. However, the
sensitivity of the HER2 classification of the discovery set
would have decreased to 0.47 when compared with the
“gold standard” IHC assay. Using the HER2 IHC assay,
several groups have reported false-positive HER2
overexpression results, especially in the group with
HER IHC 2.65,66,75 The agreement, kappa, of HER2
overexpression status between the IHC assay and the
mERPRHER2 assay with the 		CT cutoff-point method
for both discovery and validation sets (Table 8) were
higher than kappa of 0.60 with the HER2 TaqMan assay
in the Oncotype DX.63 The samples with HER2, IHC 2
and 3 status in our study were under represented in our
HER2 validation set due to the high percentage of ER
samples in the sample set. Therefore, we will continue to
evaluate both 		CT cutoff-point and clustering methods for
classification of HER2 overexpression, and compare the
results with that of IHC and/or fluorescence in situ hybrid-
ization. Although presently the ASCO 2007 Guideline Up-
date does not recommend testing HER2 level to determine
sensitivity to endocrine therapy,32 reporting quantitative ER,
PR, and HER2 expression levels might provide a better
understanding of the cause of the resistance to tamoxifen
and non-responsiveness to trastuzmab treatments.
In conclusion, we developed a sensitive single-tube, one-
step multiplex TaqMan assay to quantitate ER, PR, and
HER2 expression levels with results shown to be consistent
across multiple adjacent sections from the same tumor. The
classification of ER, PR, and HER2-overexpression status
was evaluated with two methods and compared with IHC
results. Based on the interpretation of kappa coefficients,
the agreement was “almost perfect” for ER, and the agree-
ment was “substantial” for both PR and HER2.68 This 2-hour
RT-PCR assay to determine the ER, PR, and HER2 status
can be easily adopted in a clinical laboratory for molecular
testing of the most important predictive and prognostic
markers for breast cancer.
Acknowledgments
We thank Scott Benson and Dean Tsou at Applied Biosys-
tems for providing TaqMan probes labeled with TRE and
PHO and new passive reference dye, NPR. We thank Chris
Sigua, Henry Shu, Wontae Kim, and Cindy Christopherson
at Celera, Eddie Kallam at LabCorp, and Robert Springall at
Guy’s and St. Thomas’ Breast Tissue and Data Bank for
their technical supports to this study. We thank Tom White
and Tom Lenk for providing comments on the manuscript.
References
1. Schiff R, Osborne CK: Endocrinology and hormone therapy in breast
cancer: new insight into estrogen receptor-alpha function and its
implication for endocrine therapy resistance in breast cancer. Breast
Cancer Res 2005, 7:205–211
2. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER,
Wolmark N: National Surgical Adjuvant Breast and Bowel Project
randomised clinical trials: treatment of lymph-node-negative, oestro-
gen-receptor-positive breast cancer: long-term findings from National
Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Lancet 2004, 364:858–868
3. International Breast Cancer Study Group (IBCSG): Endocrine respon-
siveness and tailoring adjuvant therapy for postmenopausal lymph
node-negative breast cancer: a randomized trial. J Natl Cancer Inst
2002, 94:1054–1065
4. Coates AS, Keshaviah A, Thu¨rlimann B, Mouridsen H, Mauriac L,
Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni
M, La´ng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski
T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A: Five years of
letrozole compared with tamoxifen as initial adjuvant therapy for
postmenopausal women with endocrine-responsive early breast
cancer: update of study BIG 1–98. J Clin Oncol 2007, 25:486–492
5. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’
Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M:
Effect of anastrozole and tamoxifen as adjuvant treatment for early-
stage breast cancer: 100-month analysis of the ATAC trial. Lancet
Oncol 2008, 9:45–53
6. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell’Orto P,
128 Iverson et al
JMD March 2009, Vol. 11, No. 2
Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C,
Thu¨rlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhir-
sch A, Gusterson BA, Coates AS: Prognostic and predictive value of
centrally reviewed expression of estrogen and progesterone recep-
tors in a randomized trial comparing letrozole and tamoxifen adjuvant
therapy for postmenopausal early breast cancer: bIG 1–98. J Clin
Oncol 2007, 25:3846–3852
7. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin
T, Brown RW, Kova´cs A, Pillay K, Ohlschlegel C, Braye S, Grigolato P,
Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A,
Gusterson BA, Coates AS: Chemoendocrine compared with endo-
crine adjuvant therapies for node-negative breast cancer: predictive
value of centrally reviewed expression of estrogen and progesterone
receptors–International Breast Cancer Study Group. J Clin Oncol
2008, 26:1404–1410
8. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J,
Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D,
Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar
A: Relationship between quantitative estrogen and progesterone re-
ceptor expression and human epidermal growth factor receptor 2
(HER-2) status with recurrence in the Arimidex, Tamoxifen, alone or in
combination trial. J Clin Oncol 2008, 26:1059–1065
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A,
Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D,
Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M,
Lichinitser M, La´ng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter
TM, Ru¨schoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden
E, Dolci MS, Gelber RD: Herceptin Adjuvant (HERA) Trial Study Team:
trastuzumab after adjuvant chemotherapy in HER2-positive breast
cancer. N Engl J Med 2005, 353:1659–1672
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson
NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky
TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G,
Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein
PM, Ingle JN, Wolmark N: Trastuzumab plus adjuvant chemotherapy
for operable HER2-positive breast cancer. N Engl J Med 2005,
353:1673–1684
11. Hudis CA: Trastuzumab–mechanism of action and use in clinical
practice. N Engl J Med 2007, 357:39–51
12. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T,
Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E,
Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J,
Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri
M, Massimini G, Bliss JM, van de Velde C: Intergroup Exemestane
Study: a randomized trial of exemestane after two to three years of
tamoxifen therapy in postmenopausal women with primary breast
cancer. N Engl J Med 2004, 350:1081–1092
13. Osborne CK, Schiff R, Arpino G, Lee AS, Hilsenbeck VG: Endocrine
responsiveness: understanding how progesterone receptor can be
used to select endocrine therapy. Breast 2005, 14:458–465
14. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM: Proges-
terone receptor status significantly improves outcome prediction over
estrogen receptor status alone for adjuvant endocrine therapy in two
large breast cancer databases. J Clin Oncol 2003, 21:1973–1979
15. Anderson WF, Chu KC, Chatterjee N, Brawley O, Brinton LA: Tumor
variants by hormone receptor expression in white patients with node-
negative breast cancer from the surveillance, epidemiology, and end
results database. J Clin Oncol 2001, 19:18–27
16. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV: Biology of proges-
terone receptor loss in breast cancer and its implications for endo-
crine therapy. J Clin Oncol 2005, 23:7721–7735
17. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK,
Elledge RM: Estrogen receptor-positive, progesterone receptor-
negative breast cancer: association with growth factor receptor
expression and tamoxifen resistance. J Natl Cancer Inst 2005,
97:1254–1261
18. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J,
Nicholson RI, Lee AH, Robertson JF, Ellis IO: Biologic and clinical
characteristics of breast cancer with single hormone receptor posi-
tive phenotype. J Clin Oncol 2007, 25:4772–4778
19. McGuire WL: Estrogen receptors in human breast cancer. J Clin
Invest 1973, 52:73–77
20. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor
status by immunohistochemistry is superior to the ligand-binding
assay for predicting response to adjuvant endocrine therapy in breast
cancer. J Clin Oncol 1999, 17:1474–1481
21. Leake R: Detection of the oestrogen receptor (ER). immunohisto-
chemical versus cytosol measurements. Eur J Cancer 2000, 36
Suppl 4: S18–S19
22. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P,
Martino S, Osborne CK: Estrogen receptor (ER) and progesterone
receptor (PgR), by ligand-binding assay compared with ER. PgR and
pS2, by immuno-histochemistry in predicting response to tamoxifen
in metastatic breast cancer: a Southwest Oncology Group Study. Int
J Cancer 2000, 89:111–117
23. Allred DC, Harvey JM, Berardo M, Clark G: Prognostic and predictive
factors in breast cancer by immunohistochemical analysis. Mod
Pathol 1998, 11:155–168
24. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow
LG, Miller KD: Study of interlaboratory reliability and reproducibility of
estrogen and progesterone receptor assays in Europe. Documenta-
tion of poor reliability and identification of insufficient microwave
antigen retrieval time as a major contributory element of unreliable
assays. Am J Clin Pathol 2001, 115:44–58
25. Fisher ER, Anderson S, Dean S, Dabbs D, Fisher B, Siderits R,
Pritchard J, Pereira T, Geyer C, Wolmark N: Solving the dilemma of
the immunohistochemical and other methods used for scoring estro-
gen receptor and progesterone receptor in patients with invasive
breast carcinoma. Cancer 2005, 103:164–173
26. Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K, Brown A,
Yothers G, Anderson S, Smith R, Wickerham DL, Wolmark N: Real-
world performance of HER2 testing–National Surgical Adjuvant
Breast and Bowel Project experience. J Natl Cancer Inst 2002,
94:852–854
27. Reddy JC, Reimann JD, Anderson SM, Klein PM: Concordance be-
tween central and local laboratory HER2 testing from a community-
based clinical study. Clin Breast Cancer 2006, 7:153–157
28. Mann GB, Fahey VD, Feleppa F, Buchanan MR: Reliance on hormone
receptor assays of surgical specimens may compromise outcome in
patients with breast cancer. J Clin Oncol 2005, 23:5148–5154
29. Schnitt SJ: Estrogen receptor testing of breast cancer in current
clinical practice: what’s the question? J Clin Oncol 2006, 24:
1797–1799
30. Elledge RM: Tales from a targeted therapy. J Clin Oncol 2006,
24:1323–1325
31. Gown AM: Current issues in ER and HER2 testing by IHC in breast
cancer. Mod Pathol 2008, 21:S8–S15
32. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somer-
field MR, Hayes DF, Bast RC Jr: American Society of Clinical
Oncology: American Society of Clinical Oncology 2007 update of
recommendations for the use of tumor markers in breast cancer.
J Clin Oncol 2007, 25:5287–5312
33. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote
RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM,
Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C,
Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes
DF: American Society of Clinical Oncology/College of American Pa-
thologists guideline recommendations for human epidermal growth
factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007,
131:18–43
34. Chevillard S, Mu¨ller A, Levalois C, Laine´-Bidron C, Vielh P,
Magdele´nat H: Reverse transcription-polymerase chain reaction (RT-
PCR) assays of estrogen and progesterone receptors in breast can-
cer. Breast Cancer Res Treat 1996, 41:81–89
35. Tong D, Schneeberger C, Leodolter S, Zeillinger R: Quantitative
determination of gene expression by competitive reverse transcrip-
tion-polymerase chain reaction in degraded RNA samples. Anal Bio-
chem 1997, 251:173–177
36. Hackl T, Zickl M, Dobianer K, Hruza C, Czerwenka K, Spona J:
Detection of oestrogen and progesterone receptor expression in
breast tumors by semiquantitative PCR. Anticancer Res 1998,
18:839–842
37. Shepard SB, Cooper AG: Assessing the expression of two genes
simultaneously in surgical specimens using polymerase chain reac-
tion. Mod Pathol 2000, 13:401–406
38. Tong D, Schneeberger C, Czerwenka K, Schmutzler RK, Speiser P,
Kucera E, Concin N, Kubista E, Leodolter S, Zeillinger R: Messenger
RNA determination of estrogen receptor, progesterone receptor, pS2,
Multiplex TaqMan Assay for ER, PR & HER2 129
JMD March 2009, Vol. 11, No. 2
and plasminogen activator, inhibitor-1 by competitive reverse tran-
scription polymerase chain reaction in human breast cancer. Clin
Cancer Res 1999, 5:1497–1502
39. Iwao K, Miyoshi Y, Egawa C, Ikeda N, Tsukamoto F, Noguchi S:
Quantitative analysis of estrogen receptor-alpha and -beta messen-
ger RNA expression in breast carcinoma by real-time polymerase
chain reaction. Cancer 2000, 89:1732–1738
40. de Cremoux P, Bieche I, Tran-Perennou C, Vignaud S, Boudou E,
Asselain B, Lidereau R, Magdele´nat H, Becette V, Sigal-Zafrani B,
Spyratos F: Inter-laboratory quality control for hormone-dependent gene
expression in human breast tumors using real-time reverse transcription-
polymerase chain reaction. Endocr Relat Cancer 2004, 11:489–495
41. Labuhn M, Vuaroqueaux V, Fina F, Schaller A, Nanni-Metellus I, Kung
W, Eppenberger-Castori S, Martin PM, Eppenberger U: Simultaneous
quantitative detection of relevant biomarkers in breast cancer by
quantitative real-time PCR. Int J Biol Markers 2006, 21:30–39
42. Lamy PJ, Nanni I, Fina F, Bibeau F, Romain S, Dussert C, Penault
Llorca F, Grenier J, Ouafik LH, Martin PM: NASBA: a novel approach
to assess hormonal receptors and ERBB2 status in breast cancer.
Clin Chem Lab Med 2006, 44:3–12
43. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban
JM, Baker JB: Measurement of gene expression in archival paraffin-
embedded tissues: development and performance of a 92-gene re-
verse transcriptase-polymerase chain reaction assay. Am J Pathol
2004, 164:35–42
44. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA,
Osborne CK, Allred DC, Erlander MG: The HOXB13:IL17BR expres-
sion index is a prognostic factor in early-stage breast cancer. J Clin
Oncol 2006, 24:4611–4619
45. Bie`che I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R,
Vidaud M: Real-time reverse transcription-PCR assay for future man-
agement of ERBB2-based clinical applications. Clin Chem 1999,
45:1148–1156
46. Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg MC,
Hanna W, Wittwer CT, Seth A, Lyon E: Comparison of two quantitative
polymerase chain reaction methods for detecting HER2/neu amplifi-
cation. J Mol Diagn 2003, 5:184–190
47. Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-
Dutoit S: Real-time quantitative PCR of microdissected paraffin-em-
bedded breast carcinoma: an alternative method for HER-2/neu anal-
ysis. J Mol Diagn 2004, 6:42–51
48. Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa
C, Kaserer K, Schreiber M: Expression of HER2 and the coamplified
genes GRB7 and MLN64 in human breast cancer: quantitative real-
time reverse transcription-PCR as a diagnostic alternative to immu-
nohistochemistry and fluorescence in situ hybridization. Clin Cancer
Res 2005, 11:8348–8357
49. Potemski P, Płuciennik E, Bednarek AK, Kusin´ska R, Pasz-Walczak G,
Jesionek-Kupnicka D, Watala C, Kordek R: A comparative assess-
ment of HER2 status in operable breast cancer by real-time RT-PCR
and by immunohistochemistry. Med Sci Monit 2006, 12:MT57–MT61
50. Kostopoulou E, Vageli D, Kaisaridou D, Nakou M, Netsika M, Vladica
N, Daponte A, Koukoulis G: Comparative evaluation of non-informa-
tive HER-2 immunoreactions (2) in breast carcinomas with FISH.
CISH and QRT-PCR. Breast 2007, 16:615–624
51. Bergqvist J, Ohd JF, Smeds J, Klaar S, Isola J, Nordgren H,
Elmberger GP, Hellborg H, Bjohle J, Borg AL, Skoog L, Bergh J:
Quantitative real-time PCR analysis and microarray-based RNA ex-
pression of HER2 in relation to outcome. Ann Oncol 2007,
18:845–850
52. Barberis M, Pellegrini C, Cannone M, Arizzi C, Coggi G, Bosari S:
Quantitative PCR and HER2 testing in breast cancer: a technical
and cost-effectiveness analysis. Am J Clin Pathol 2008,
129:563–570
53. Tutt A, Wang A, Rowland C, Gillett C, L Kit L, Chew K, Dai H, Kwok S,
Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L,
Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T,
Broder S, Sninsky J, Brandt B, Waldman F: Risk estimation of distant
metastasis in node-negative, estrogen receptor-positive breast can-
cer patients using an RT-PCR based prognostic expression signa-
ture. BMC Cancer 2008, 8:339
54. Livak KJ, Schmittgen TD: Analysis of relative gene expression data
using real-time quantitative PCR and the 2-		CT Method. Methods
2001, 25:402–408
55. DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas
under two or more correlated receiver operating characteristic
curves: a nonparametric approach. Biometrics 1988, 44:837–845
56. R Development Core Team. R: a language and environment for
statistical computing. R Foundation for Statistical Computing 2006,
Vienna, Austria. ISBN 3-900051-07-0
57. Banfield JD, Raftery AE: Model-based Gaussian and non-Gaussian
Clustering. Biometrics 1993, 49:803–821
58. Fraley C, Raftery AE: MCLUST: software for model-based cluster
analysis. J Class 1999, 16:297–306
59. Fraley C, Raftery AE: Technical Report No. 415, Dept. of Statistics,
Univ. of Washington, Oct. 2002
60. Fraley C, Raftery AE: Model-based clustering, discriminant analysis
and density estimation. J Am Stat Assoc 2002, 97:611–631
61. Fraley C, Raftery AE: Enhanced model-based clustering. Density
estimation, and discriminant analysis software: mCLUST. J Class
2003, 20:263–286
62. Cohen J: A coefficient of agreement for nominal scales. Educ Psychol
Meas 1960, 20:37–46
63. Esteva FJ, Sahin AA, Cristofanilli M, Coombes K, Lee SJ, Baker J,
Cronin M, Walker M, Watson D, Shak S, Hortobagyi GN: Prognostic
role of a multigene reverse transcriptase-PCR assay in patients with
node-negative breast cancer not receiving adjuvant systemic ther-
apy. Clin Cancer Res 2005, 11:3315–3319
64. Chang JC, Makris A, Gutierrez MC, Hilsenbeck SG, Hackett JR,
Jeong J, Liu ML, Baker J, Clark-Langone K, Baehner FL, Sexton K,
Mohsin S, Gray T, Alvarez L, Chamness GC, Osborne CK, Shak S:
Gene expression patterns in formalin-fixed, paraffin-embedded core
biopsies predict docetaxel chemosensitivity in breast cancer pa-
tients. Breast Cancer Res Treat 2008, 108:233–240
65. Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher
DW: Analysis of intratumoral heterogeneity and amplification status in
breast carcinomas with equivocal (2) HER-2 immunostaining. Am J
Clin Pathol 2005, 124:273–281
66. Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C: The complexity
of genotypic alterations underlying HER2-positive breast cancer: an
explanation for its clinical heterogeneity. Curr Opin Oncol 2007,
19:552–557
67. Cheang MC, Treaba DO, Speers CH, Olivotto IA, Bajdik CD, Chia SK,
Goldstein LC, Gelmon KA, Huntsman D, Gilks CB, Nielsen TO, Gown
AM: Immunohistochemical detection using the new rabbit monoclo-
nal antibody SP1 of estrogen receptor in breast cancer is superior to
mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol
2006, 24:5637–5644
68. Landis JR, Koch GG: The measurement of observer agreement for
categorical data. Biometrics 1977, 33:159–174
69. Kastner P, Krust A, Turcotte B, Stropp U, Tora L, Gronemeyer H,
Chambon P: Two distinct estrogen-regulated promoters generate
transcripts encoding the two functionally different human progester-
one receptor forms A and B. EMBO J 1990, 9:1603–1614
70. Balleine RL, Hunt SM, Clarke CL: Coexpression of alternatively
spliced estrogen and progesterone receptor transcripts in human
breast cancer. J Clin Endocrinol Metab 1999, 84:1370–1377
71. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z,
Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M,
Seshadri R, Hepp H, Slamon DJ: Quantitative association between
HER-2/neu and steroid hormone receptors in hormone receptor-pos-
itive primary breast cancer. J Natl Cancer Inst 2003, 95:142–153
72. Osborne CK, Shou J, Massarweh S, Schiff R: Crosstalk between
estrogen receptor and growth factor receptor pathways as a cause
for endocrine therapy resistance in breast cancer. Clin Cancer Res
2005, 15:865s–870s
73. Kim HJ, Cui X, Hilsenbeck SG, Lee AV: Progesterone receptor loss
correlates with human epidermal growth factor receptor 2 overex-
pression in estrogen receptor-positive breast cancer. Clin Cancer
Res 2006, 12:1013S–1018S
74. Ciocca DR, Gago FE, Fanelli MA, Calderwood SK: Co-expression of
steroid receptors (estrogen receptor alpha and/or progesterone re-
ceptors) and Her-2/neu: clinical implications. J Steroid Biochem Mol
Biol 2006, 102:32–40
75. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM:
Discrepancies in clinical laboratory testing of eligibility for trastu-
zumab therapy: apparent immunohistochemical false-positives do
not get the message. J Clin Oncol. 2001, 19:2714–2721
130 Iverson et al
JMD March 2009, Vol. 11, No. 2
